[go: up one dir, main page]

RU2012130015A - TEMM22 PEPTIDES AND INCLUDING THEIR VACCINES - Google Patents

TEMM22 PEPTIDES AND INCLUDING THEIR VACCINES Download PDF

Info

Publication number
RU2012130015A
RU2012130015A RU2012130015/10A RU2012130015A RU2012130015A RU 2012130015 A RU2012130015 A RU 2012130015A RU 2012130015/10 A RU2012130015/10 A RU 2012130015/10A RU 2012130015 A RU2012130015 A RU 2012130015A RU 2012130015 A RU2012130015 A RU 2012130015A
Authority
RU
Russia
Prior art keywords
peptide
peptide according
amino acid
hla
group
Prior art date
Application number
RU2012130015/10A
Other languages
Russian (ru)
Inventor
Юсуке Накамура
Такуя Цунода
Рюдзи ОХСАВА
Сатико Йосимура
Томохиса Ватанабе
Original Assignee
Онкотерапи Сайенс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкотерапи Сайенс, Инк. filed Critical Онкотерапи Сайенс, Инк.
Publication of RU2012130015A publication Critical patent/RU2012130015A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Выделенный пептид, который связывается с HLA-антигеном и обладает способностью индуцирования цитотоксических T-лимфоцитов (ЦТЛ), где пептид состоит из аминокислотной последовательности SEQ ID NO: 92 или ее иммунологически-активного фрагмента.2. Выделенный пептид по п.1, где HLA-антиген представляет собой HLA-A24 или HLA-A2.3. Выделенный пептид по п.1, где указанный пептид включает аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 1-16, 18-32 и 34-90.4. Выделенный пептид по п.3, который состоит из аминокислотной последовательности, выбранной из группы: SEQ ID NO: 1, 2, 3, 4, 5, 6, 10, 12, 16, 18, 19, 22, 28, 31, 35, 38, 41, 48, 61, 62, 65, 67, 70, 74, 77 и 83.5. Выделенный пептид по п.1, где указанный пептид состоит из аминокислотной последовательности, выбранной из группы, состоящей из SEQ ID NO: 1-16, 18-32 и 34-90, где 1, 2 или несколько аминокислот вставлены, заменены, делетированы или добавлены.6. Выделенный пептид по п.5, где в контексте HLA-A24, пептид обладает одной или двумя из следующих характеристик:(a) вторая аминокислота от N-конца выбрана из группы, состоящей из фенилаланина, тирозина, метионина и триптофана; и(b) C-концевая аминокислота выбрана из группы, состоящей из фенилаланина, лейцина, изолейцина, триптофана и метионина.7. Выделенный пептид по п.5, где в контексте HLA-A2, пептид обладает одной или двумя из следующих характеристик:(a) вторая аминокислота от N-конца выбрана из группы, состоящей из лейцина и метионина; и(b) C-концевая аминокислота выбрана из группы, состоящей из валина и лейцина.8. Выделенный пептид по любому из пп.1-7, где указанный пептид представляет собой нонапептид или декапептид.9. Выделенный полинуклеотид, кодирующий пептид по любому из пп.1-8.10. Агент для инд1. The selected peptide that binds to the HLA antigen and has the ability to induce cytotoxic T lymphocytes (CTLs), where the peptide consists of the amino acid sequence of SEQ ID NO: 92 or its immunologically active fragment. The selected peptide according to claim 1, where the HLA antigen is HLA-A24 or HLA-A2.3. The selected peptide according to claim 1, wherein said peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-16, 18-32, and 34-90.4. The selected peptide according to claim 3, which consists of an amino acid sequence selected from the group: SEQ ID NO: 1, 2, 3, 4, 5, 6, 10, 12, 16, 18, 19, 22, 28, 31, 35 , 38, 41, 48, 61, 62, 65, 67, 70, 74, 77, and 83.5. The selected peptide according to claim 1, where the specified peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-16, 18-32 and 34-90, where 1, 2 or more amino acids are inserted, replaced, deleted or added. 6. The selected peptide according to claim 5, where in the context of HLA-A24, the peptide has one or two of the following characteristics: (a) the second amino acid from the N-terminus is selected from the group consisting of phenylalanine, tyrosine, methionine and tryptophan; and (b) the C-terminal amino acid is selected from the group consisting of phenylalanine, leucine, isoleucine, tryptophan and methionine. 7. The selected peptide according to claim 5, where in the context of HLA-A2, the peptide has one or two of the following characteristics: (a) the second amino acid from the N-terminus is selected from the group consisting of leucine and methionine; and (b) the C-terminal amino acid is selected from the group consisting of valine and leucine. 8. An isolated peptide according to any one of claims 1 to 7, wherein said peptide is a nonapeptide or decapeptide. An isolated polynucleotide encoding a peptide according to any one of claims 1 to 8.10. Agent for ind

Claims (21)

1. Выделенный пептид, который связывается с HLA-антигеном и обладает способностью индуцирования цитотоксических T-лимфоцитов (ЦТЛ), где пептид состоит из аминокислотной последовательности SEQ ID NO: 92 или ее иммунологически-активного фрагмента.1. The selected peptide that binds to the HLA antigen and has the ability to induce cytotoxic T lymphocytes (CTLs), where the peptide consists of the amino acid sequence of SEQ ID NO: 92 or its immunologically active fragment. 2. Выделенный пептид по п.1, где HLA-антиген представляет собой HLA-A24 или HLA-A2.2. The selected peptide according to claim 1, where the HLA antigen is HLA-A24 or HLA-A2. 3. Выделенный пептид по п.1, где указанный пептид включает аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 1-16, 18-32 и 34-90.3. The selected peptide according to claim 1, where the specified peptide includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1-16, 18-32 and 34-90. 4. Выделенный пептид по п.3, который состоит из аминокислотной последовательности, выбранной из группы: SEQ ID NO: 1, 2, 3, 4, 5, 6, 10, 12, 16, 18, 19, 22, 28, 31, 35, 38, 41, 48, 61, 62, 65, 67, 70, 74, 77 и 83.4. The selected peptide according to claim 3, which consists of an amino acid sequence selected from the group: SEQ ID NO: 1, 2, 3, 4, 5, 6, 10, 12, 16, 18, 19, 22, 28, 31 , 35, 38, 41, 48, 61, 62, 65, 67, 70, 74, 77, and 83. 5. Выделенный пептид по п.1, где указанный пептид состоит из аминокислотной последовательности, выбранной из группы, состоящей из SEQ ID NO: 1-16, 18-32 и 34-90, где 1, 2 или несколько аминокислот вставлены, заменены, делетированы или добавлены.5. The selected peptide according to claim 1, where the specified peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1-16, 18-32 and 34-90, where 1, 2 or more amino acids are inserted, replaced, deleted or added. 6. Выделенный пептид по п.5, где в контексте HLA-A24, пептид обладает одной или двумя из следующих характеристик:6. The selected peptide according to claim 5, where in the context of HLA-A24, the peptide has one or two of the following characteristics: (a) вторая аминокислота от N-конца выбрана из группы, состоящей из фенилаланина, тирозина, метионина и триптофана; и(a) the second amino acid from the N-terminus is selected from the group consisting of phenylalanine, tyrosine, methionine and tryptophan; and (b) C-концевая аминокислота выбрана из группы, состоящей из фенилаланина, лейцина, изолейцина, триптофана и метионина.(b) The C-terminal amino acid is selected from the group consisting of phenylalanine, leucine, isoleucine, tryptophan and methionine. 7. Выделенный пептид по п.5, где в контексте HLA-A2, пептид обладает одной или двумя из следующих характеристик:7. The selected peptide according to claim 5, where in the context of HLA-A2, the peptide has one or two of the following characteristics: (a) вторая аминокислота от N-конца выбрана из группы, состоящей из лейцина и метионина; и(a) the second amino acid from the N-terminus is selected from the group consisting of leucine and methionine; and (b) C-концевая аминокислота выбрана из группы, состоящей из валина и лейцина.(b) The C-terminal amino acid is selected from the group consisting of valine and leucine. 8. Выделенный пептид по любому из пп.1-7, где указанный пептид представляет собой нонапептид или декапептид.8. The selected peptide according to any one of claims 1 to 7, where the specified peptide is a nonapeptide or decapeptide. 9. Выделенный полинуклеотид, кодирующий пептид по любому из пп.1-8.9. The selected polynucleotide encoding the peptide according to any one of claims 1 to 8. 10. Агент для индуцирования ЦТЛ, где агент включает один или более пептидов по любому из пп.1-8, или один или более полинуклеотидов по п.9.10. An agent for inducing CTLs, where the agent includes one or more peptides according to any one of claims 1 to 8, or one or more polynucleotides according to claim 9. 11. Фармацевтический агент для лечения и/или профилактики рака и/или для предотвращения его послеоперационного рецидива, где агент включает один или более пептидов по любому из пп.1-8, или один или более полинуклеотидов по п.9.11. A pharmaceutical agent for treating and / or preventing cancer and / or for preventing its postoperative relapse, wherein the agent comprises one or more peptides according to any one of claims 1 to 8, or one or more polynucleotides according to claim 9. 12. Фармацевтический агент по п.11, где указанный агент приготовляют в виде состава для введения объекту, у которого HLA-антиген представляет собой HLA-A24 или HLA-A2.12. The pharmaceutical agent of claim 11, wherein said agent is formulated for administration to an object in which the HLA antigen is HLA-A24 or HLA-A2. 13. Способ индуцирования антиген-презентирующей клетки (АПК) со способностью индуцирования ЦТЛ, где способ включает одну из следующих стадий:13. A method of inducing an antigen-presenting cell (APC) with the ability to induce CTLs, where the method comprises one of the following steps: (a) приведение АПК в контакт с пептидом по любому из пп.1-8 in vitro, ex vivo или in vivo; и(a) bringing the APC into contact with the peptide according to any one of claims 1 to 8 in vitro , ex vivo or in vivo ; and (b) введение полинуклеотида, кодирующего пептид по любому из пп.1-8, в АПК.(b) introducing a polynucleotide encoding the peptide according to any one of claims 1 to 8, in the APC. 14. Способ индуцирования ЦТЛ с помощью любого из способов, включающий, по меньшей мере, одну из следующих стадий:14. A method of inducing CTLs using any of the methods, comprising at least one of the following steps: (a) совместное культивирование CD8-положительных T-клеток с АПК, которые презентируют на своей поверхности комплекс HLA-антигена и пептида по любому из пп.1-8;(a) co-culturing CD8-positive T cells with APCs that present on their surface a complex of the HLA antigen and peptide according to any one of claims 1 to 8; (b) совместное культивирование CD8-положительных T-клеток с экзосомами, которые презентируют на своей поверхности комплекс HLA-антигена и пептида по любому из пп.1-8; и(b) co-culturing CD8-positive T cells with exosomes that present on their surface a complex of the HLA antigen and peptide according to any one of claims 1 to 8; and (c) введение в Т-клетку гена, который включает полинуклеотид, кодирующий полипептид субъединицы T-клеточного рецептора (TCR), связывающегося с пептидом по любому из пп.1-8.(c) introducing into a T cell a gene that comprises a polynucleotide encoding a T cell receptor (TCR) subunit polypeptide that binds to the peptide according to any one of claims 1 to 8. 15. Выделенная АПК, которая презентирует на своей поверхности комплекс HLA-антигена и пептида по любому из пп.1-8.15. Isolated APC, which presents on its surface a complex of HLA antigen and peptide according to any one of claims 1 to 8. 16. АПК по п.15, которая индуцируется с помощью способа по п.13.16. The APC according to clause 15, which is induced using the method according to clause 13. 17. Выделенный ЦТЛ, мишенью которого является пептид по любому из пп.1-8.17. An isolated CTL whose target is a peptide according to any one of claims 1 to 8. 18. ЦТЛ по п.17, который индуцируется с помощью способа по п.14.18. CTL according to 17, which is induced using the method according to 14. 19. Способ индуцирования у субъекта иммунного ответа против рака, включающий введение субъекту агента, включающего пептид по любому из пп.1-8, его иммунологически-активный фрагмент, полинуклеотид, кодирующий пептид или его фрагмент.19. A method of inducing an anti-cancer immune response in a subject, comprising administering to the subject an agent comprising a peptide according to any one of claims 1 to 8, an immunologically active fragment thereof, a polynucleotide encoding a peptide or fragment thereof. 20. Вектор, включающий нуклеотидную последовательность, кодирующую пептид по любому из пп.1-8.20. A vector comprising a nucleotide sequence encoding a peptide according to any one of claims 1 to 8. 21. Клетка-хозяин, трансформированная или трансфицированная экспрессирующим вектором по п.20. 21. A host cell transformed or transfected with the expression vector of claim 20.
RU2012130015/10A 2009-12-14 2010-12-13 TEMM22 PEPTIDES AND INCLUDING THEIR VACCINES RU2012130015A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28621309P 2009-12-14 2009-12-14
US61/286,213 2009-12-14
US28765009P 2009-12-17 2009-12-17
US61/287,650 2009-12-17
US32638010P 2010-04-21 2010-04-21
US61/326,380 2010-04-21
PCT/JP2010/007228 WO2011074236A1 (en) 2009-12-14 2010-12-13 Tmem22 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
RU2012130015A true RU2012130015A (en) 2014-01-27

Family

ID=44167006

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012130015/10A RU2012130015A (en) 2009-12-14 2010-12-13 TEMM22 PEPTIDES AND INCLUDING THEIR VACCINES

Country Status (14)

Country Link
US (2) US8697631B2 (en)
EP (1) EP2513136A4 (en)
JP (1) JP2013513549A (en)
KR (1) KR20120104350A (en)
CN (1) CN102770441A (en)
AU (1) AU2010331648A1 (en)
BR (1) BR112012014345A2 (en)
CA (1) CA2782977A1 (en)
IL (1) IL220146A0 (en)
MX (1) MX2012006770A (en)
RU (1) RU2012130015A (en)
SG (2) SG181530A1 (en)
TW (1) TW201136604A (en)
WO (1) WO2011074236A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890202B2 (en) 2010-07-19 2018-02-13 Yeda Research And Development Co. Ltd. Peptides based on the transmembrane domain of a toll-like receptor (TLR) for treatment of TLR-mediated diseases
EP2766384B1 (en) * 2011-10-10 2016-11-23 Yeda Research and Development Co. Ltd. Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
CN105814073A (en) * 2012-12-04 2016-07-27 肿瘤疗法科学股份有限公司 SEMA5B peptides and vaccine comprising same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
CA2284109A1 (en) 1997-03-19 1998-09-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
FR2766205B1 (en) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
EP2336167B1 (en) 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2327040T3 (en) * 2002-09-12 2009-10-23 Oncotherapy Science, Inc. KDR PEPTIDES AND VACCINES THAT CONTAIN THEM.
CA2580412A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
JP2009502112A (en) 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 Methods for diagnosing and treating renal cell carcinoma
KR101130597B1 (en) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 T-cell receptor and nucleic acid encoding the receptor
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
TWI434853B (en) 2007-04-11 2014-04-21 Oncotherapy Science Inc Tem8 peptides and vaccines comprising the same
TW200932260A (en) 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
EP2254899A4 (en) 2008-02-15 2012-05-30 Pacific Arrow Ltd Blocking the metastasis of cancer cells and the uses of new compounds thereof

Also Published As

Publication number Publication date
US20140199336A1 (en) 2014-07-17
JP2013513549A (en) 2013-04-22
EP2513136A1 (en) 2012-10-24
KR20120104350A (en) 2012-09-20
US8697631B2 (en) 2014-04-15
SG10201408245WA (en) 2015-01-29
CA2782977A1 (en) 2011-06-23
BR112012014345A2 (en) 2017-01-10
WO2011074236A1 (en) 2011-06-23
MX2012006770A (en) 2012-07-20
CN102770441A (en) 2012-11-07
IL220146A0 (en) 2012-07-31
AU2010331648A1 (en) 2012-06-21
TW201136604A (en) 2011-11-01
US20120308591A1 (en) 2012-12-06
SG181530A1 (en) 2012-07-30
EP2513136A4 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
RU2011138160A (en) FOXMI PEPTIDES AND VACCINES CONTAINING THEM
RU2009141595A (en) TEM8 PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2009118432A (en) PEPTIDE VACCINES AGAINST CANCER WITH EXPRESSION OF MPHOSPH1 OR DEPDC1 POLYPEPTIDES
RU2011101709A (en) CDCA1 EPITOPE-PEPTIDES AND THEIR VACCINES CONTAINING THEM
JP2012517799A5 (en)
JP2011524737A5 (en)
JP2010523471A5 (en)
RU2012127358A (en) OLIGOPEPTIDES IMP-3 AND THEIR VACCINES CONTAINING THEM
RU2010154081A (en) EPITOPIC PEPTIDES IQGAP3 VACCINES CONTAINING THEM
RU2014121502A (en) TORK PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2012136464A (en) MELK MODIFIED PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2015143164A (en) KNTC2 PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2010154101A (en) MYBL2 EPITOPE PEPTIDES AND THEIR VACCINES CONTAINING THEM
JP2011522777A5 (en)
RU2015113436A (en) UBE2T PEPTIDES AND THEIR VACCINES CONTAINING THEM
RU2012147590A (en) CDCA5 PEPTIDES AND THEIR VACCINES CONTAINING THEM
JP2013523084A5 (en)
RU2014109137A (en) MPHOSPH1 PEPTIDES AND VACCINES INCLUDING THEM
RU2013158399A (en) SEMA5B PEPTIDES AND THEIR VACCINES CONTAINING THEM
JP2015529219A5 (en)
JP2013517764A5 (en)
JP2014519311A5 (en)
RU2011152975A (en) CDC45L PEPTIDES AND VACCINES INCLUDING SUCH
RU2010126154A (en) EPITOPE PEPTIDES STAT3
RU2011150283A (en) TTK PEPTIDES AND VACCINES THEREOF

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20160614